119 related articles for article (PubMed ID: 22936125)
1. Fatigue in patients with systemic lupus erythematosus: the role of dehydroepiandrosterone sulphate.
Overman CL; Hartkamp A; Bossema ER; Bijl M; Godaert GL; Bijlsma JW; Derksen RH; Geenen R
Lupus; 2012 Dec; 21(14):1515-21. PubMed ID: 22936125
[TBL] [Abstract][Full Text] [Related]
2. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
Barry NN; McGuire JL; van Vollenhoven RF
J Rheumatol; 1998 Dec; 25(12):2352-6. PubMed ID: 9858429
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones.
Vogl D; Falk W; Dorner M; Schölmerich J; Straub RH
J Rheumatol; 2003 Feb; 30(2):269-75. PubMed ID: 12563679
[TBL] [Abstract][Full Text] [Related]
4. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
Hartkamp A; Geenen R; Godaert GL; Bijl M; Bijlsma JW; Derksen RH
Ann Rheum Dis; 2010 Jun; 69(6):1144-7. PubMed ID: 19854713
[TBL] [Abstract][Full Text] [Related]
5. Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus.
Straub RH; Zeuner M; Antoniou E; Schölmerich J; Lang B
J Rheumatol; 1996 May; 23(5):856-61. PubMed ID: 8724298
[TBL] [Abstract][Full Text] [Related]
6. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus.
Formiga F; Moga I; Nolla JM; Navarro MA; Bonnin R; Roig-Escofet D
Clin Exp Rheumatol; 1997; 15(4):387-92. PubMed ID: 9272299
[TBL] [Abstract][Full Text] [Related]
7. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
Cleare AJ; O'Keane V; Miell JP
Psychoneuroendocrinology; 2004 Jul; 29(6):724-32. PubMed ID: 15110921
[TBL] [Abstract][Full Text] [Related]
8. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus.
Straub RH; Weidler C; Demmel B; Herrmann M; Kees F; Schmidt M; Schölmerich J; Schedel J
Ann Rheum Dis; 2004 Aug; 63(8):961-8. PubMed ID: 15249323
[TBL] [Abstract][Full Text] [Related]
9. Reduced plasma dehydroepiandrosterone sulfate levels are significantly correlated with fatigue severity in patients with primary biliary cirrhosis.
Ahboucha S; Pomier-Layrargues G; Vincent C; Hassoun Z; Tamaz R; Baker G; Butterworth RF
Neurochem Int; 2008; 52(4-5):569-74. PubMed ID: 17669554
[TBL] [Abstract][Full Text] [Related]
10. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
van Vollenhoven RF; Morabito LM; Engleman EG; McGuire JL
J Rheumatol; 1998 Feb; 25(2):285-9. PubMed ID: 9489820
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjögren's syndrome.
Virkki LM; Porola P; Forsblad-d'Elia H; Valtysdottir S; Solovieva SA; Konttinen YT
Arthritis Care Res (Hoboken); 2010 Jan; 62(1):118-24. PubMed ID: 20191499
[TBL] [Abstract][Full Text] [Related]
12. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor.
Zietz B; Reber T; Oertel M; Glück T; Schölmerich J; Straub RH
J Rheumatol; 2000 Apr; 27(4):911-8. PubMed ID: 10782815
[TBL] [Abstract][Full Text] [Related]
13. Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease.
Khaw KT
J Endocrinol; 1996 Sep; 150 Suppl():S149-53. PubMed ID: 8943798
[TBL] [Abstract][Full Text] [Related]
14. Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis.
Härle P; Pongratz G; Weidler C; Büttner R; Schölmerich J; Straub RH
Ann Rheum Dis; 2004 Jul; 63(7):809-16. PubMed ID: 15194576
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus.
Sarkissian T; Beyene J; Feldman B; McCrindle B; Silverman ED
Arthritis Rheum; 2007 Feb; 56(2):631-8. PubMed ID: 17265498
[TBL] [Abstract][Full Text] [Related]
16. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus.
Nordmark G; Bengtsson C; Larsson A; Karlsson FA; Sturfelt G; Rönnblom L
Autoimmunity; 2005 Nov; 38(7):531-40. PubMed ID: 16373258
[TBL] [Abstract][Full Text] [Related]
17. Low sulpho-conjugated steroid hormone levels in systemic lupus erythematosus (SLE).
Hedman M; Nilsson E; de la Torre B
Clin Exp Rheumatol; 1989; 7(6):583-8. PubMed ID: 2533000
[TBL] [Abstract][Full Text] [Related]
18. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery.
Kozora E; Ellison MC; West S
Arthritis Rheum; 2006 Aug; 55(4):628-35. PubMed ID: 16874786
[TBL] [Abstract][Full Text] [Related]
19. In vitro modulatory effect of dehydroepiandrosterone sulfate on apoptosis and expression of apoptosis-related genes in patients with systemic lupus erythematosus.
Yousefi B; Rastin M; Hatef MR; Shariati J; Alimohammadi R; Mahmoudi M
J Cell Physiol; 2019 Aug; 234(8):12676-12684. PubMed ID: 30536399
[TBL] [Abstract][Full Text] [Related]
20. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
